Követés
Jan Budczies
Jan Budczies
Professor of Bioinformatics, Institute of Pathology, University Hospital Heidelberg
E-mail megerősítve itt: med.uni-heidelberg.de
Cím
Hivatkozott rá
Hivatkozott rá
Év
An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients
B Györffy, A Lanczky, AC Eklund, C Denkert, J Budczies, Q Li, Z Szallasi
Breast cancer research and treatment 123 (3), 725-731, 2010
25642010
Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer
C Denkert, S Loibl, A Noske, M Roller, BM Muller, M Komor, J Budczies, ...
J Clin Oncol 28 (1), 105-113, 2010
15762010
Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancer
B Győrffy, P Surowiak, J Budczies, A Lánczky
PloS one 8 (12), e82241, 2013
14962013
Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy
C Denkert, G von Minckwitz, S Darb-Esfahani, B Lederer, BI Heppner, ...
The lancet oncology 19 (1), 40-50, 2018
10282018
Cutoff Finder: a comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization
J Budczies, F Klauschen, BV Sinn, B Győrffy, WD Schmitt, ...
PloS one 7 (12), e51862, 2012
9382012
The novel histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification system of lung adenocarcinoma …
A Warth, T Muley, M Meister, A Stenzinger, M Thomas, P Schirmacher, ...
Journal of clinical oncology 30 (13), 1438-1446, 2012
5912012
Novel Theranostic Opportunities Offered by Characterization of Altered Membrane Lipid Metabolism in Breast Cancer ProgressionLipidomic Changes in Breast Cancer Progression
M Hilvo, C Denkert, L Lehtinen, B Müller, S Brockmöller, ...
Cancer research 71 (9), 3236-3245, 2011
4822011
Mass spectrometry–based metabolic profiling reveals different metabolite patterns in invasive ovarian carcinomas and ovarian borderline tumors
C Denkert, J Budczies, T Kind, W Weichert, P Tablack, J Sehouli, ...
Cancer research 66 (22), 10795-10804, 2006
4372006
Metabolite profiling of human colon carcinoma–deregulation of TCA cycle and amino acid turnover
C Denkert, J Budczies, W Weichert, G Wohlgemuth, M Scholz, T Kind, ...
Molecular cancer 7 (1), 1-15, 2008
3462008
Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial
C Denkert, S Loibl, BM Müller, H Eidtmann, WD Schmitt, W Eiermann, ...
Annals of oncology 24 (11), 2786-2793, 2013
2282013
Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma
S Darb-Esfahani, CA Kunze, H Kulbe, J Sehouli, S Wienert, J Lindner, ...
Oncotarget 7 (2), 1486, 2016
2202016
Differential expression of histone deacetylases HDAC1, 2 and 3 in human breast cancer-overexpression of HDAC2 and HDAC3 is associated with clinicopathological indicators of …
BM Müller, L Jana, A Kasajima, A Lehmann, J Prinzler, J Budczies, ...
BMC cancer 13 (1), 1-8, 2013
2202013
The landscape of metastatic progression patterns across major human cancers
J Budczies, M von Winterfeld, F Klauschen, M Bockmayr, JK Lennerz, ...
Oncotarget 6 (1), 570, 2015
2042015
Hyperactivation of the insulin-like growth factor receptor I signaling pathway is an essential event for cisplatin resistance of ovarian cancer cells
N Eckstein, K Servan, B Hildebrandt, A Pölitz, G Jonquières, ...
Cancer research 69 (7), 2996-3003, 2009
2022009
Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group
C Denkert, S Wienert, A Poterie, S Loibl, J Budczies, S Badve, ...
Modern Pathology 29 (10), 1155-1164, 2016
2012016
A meta-analysis of gene expression-based biomarkers predicting outcome after tamoxifen treatment in breast cancer
Z Mihály, M Kormos, A Lánczky, M Dank, J Budczies, MA Szász, B Győrffy
Breast cancer research and treatment 140 (2), 219-232, 2013
1832013
Strategies for developing Ki67 as a useful biomarker in breast cancer
C Denkert, J Budczies, G von Minckwitz, S Wienert, S Loibl, F Klauschen
The Breast 24, S67-S72, 2015
1692015
Heterogeneous expression of Wnt/β‐catenin target genes within colorectal cancer
F Hlubek, T Brabletz, J Budczies, S Pfeiffer, A Jung, T Kirchner
International journal of cancer 121 (9), 1941-1948, 2007
1612007
Comparative metabolomics of estrogen receptor positive and estrogen receptor negative breast cancer: alterations in glutamine and beta-alanine metabolism
J Budczies, SF Brockmöller, BM Müller, DK Barupal, C Richter-Ehrenstein, ...
Journal of proteomics 94, 279-288, 2013
1582013
Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated …
S Darb-Esfahani, S Loibl, BM Müller, M Roller, C Denkert, M Komor, ...
Breast Cancer Research 11 (5), 1-11, 2009
1432009
A rendszer jelenleg nem tudja elvégezni a műveletet. Próbálkozzon újra később.
Cikkek 1–20